Skip to content
Screener

Stoke Therapeutics, Inc. STOK Cash & Equivalents

Cash & Equivalents at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$350.07M+17.7%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$667.5M-64.1%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$119.53M-11.7%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$474.76M+201%
CalAmp logo
CalAmpCAMP
$100.83M+97.9%
Harmony Biosciences Holdings, Inc. logo
Harmony Biosciences Holdings, Inc.HRMY
$589.4M+20.5%

Other financials

Income statement

See full
Revenue$6.2M-96.1%
Operating income-$53.4M-148%
Net income-$50.0M-144%
EPS (diluted)-$0.79-142%

Balance sheet

See full
Total debt$3.4M-42.5%
Total equity$394.9M+12.8%
Total assets$443.3M+8.9%

Cash flow

See full
Operating cash flow-$60.6M-146%
CapEx$353.0K+132%
Free cash flow-$60.9M-146%

Valuation

See full
Market cap$2.06B+187%
Enterprise value$1.91B+206%
P/S64.2×+60.6×

Profitability

See full
Operating margin-577.5%-597pp
Net margin-529.2%-556pp
FCF margin36.2%+18.4pp

Returns & leverage

See full
Return on equity-45.6%-66.1pp
Debt / equity0×0.0×
Current ratio9×+0.6×

Where this comes from

Reported directly by Stoke Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:06 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211874
Line itemMarch 31, 2026December 31, 2025
Assets
Current assets:
Cash and cash equivalents$155,659$84,220
Marketable securities - current187,886200,450
Accounts receivable4,4515,936
Prepaid expenses10,1158,736
Interest receivable1,6901,969
Other current assets6,8804,389

Item 1. Financial Statements.

FAQ

What is Stoke Therapeutics, Inc.'s cash & equivalents?
Stoke Therapeutics, Inc. (STOK) reported cash & equivalents of $155.66M in Q1 2026.
How has Stoke Therapeutics, Inc.'s cash & equivalents changed year-over-year?
Stoke Therapeutics, Inc.'s cash & equivalents decreased by 43.4% year-over-year, from $274.82M to $155.66M.
What is the long-term trend for Stoke Therapeutics, Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s cash & equivalents has grown at a -21.8% compound annual growth rate (CAGR), from $287.31M to $84.22M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Stoke Therapeutics, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude